Blackstone backs Alnylam with up to $2B investment
Alnylam Pharmaceuticals has entered into what it claims is one of the largest ever private financings of a biotech company, announcing a potentially $2B investment from private equity firm Blackstone.
Blackstone will pay $1B in exchange for half of Alnylam’s share of royalties and commercial milestones tied to an experimental heart drug. Additionally, Blackstone will purchase $100M worth of Alnylam stock, provide up to $150M for Alnylam to develop two of its other cardiometabolic drugs, and offer a loan worth up to $750M.
